MX2022010902A - Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa. - Google Patents
Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa.Info
- Publication number
- MX2022010902A MX2022010902A MX2022010902A MX2022010902A MX2022010902A MX 2022010902 A MX2022010902 A MX 2022010902A MX 2022010902 A MX2022010902 A MX 2022010902A MX 2022010902 A MX2022010902 A MX 2022010902A MX 2022010902 A MX2022010902 A MX 2022010902A
- Authority
- MX
- Mexico
- Prior art keywords
- lateral sclerosis
- amyotrophic lateral
- treating amyotrophic
- myeloperoxidase inhibitor
- myeloperoxidase
- Prior art date
Links
- 229940122159 Myeloperoxidase inhibitor Drugs 0.000 title abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporciona un método para tratar la esclerosis lateral amiotrófica, que incluye administrar a un sujeto que necesite tal tratamiento una cantidad eficaz de un inhibidor de la mieloperoxidasa o una sal aceptable desde el punto de vista farmacéutico de esta.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062985802P | 2020-03-05 | 2020-03-05 | |
PCT/US2021/020979 WO2021178734A1 (en) | 2020-03-05 | 2021-03-05 | Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022010902A true MX2022010902A (es) | 2022-10-07 |
Family
ID=77613802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022010902A MX2022010902A (es) | 2020-03-05 | 2021-03-05 | Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230130225A1 (es) |
EP (1) | EP4114370A4 (es) |
JP (1) | JP2023519662A (es) |
KR (1) | KR20220149709A (es) |
CN (1) | CN115916164A (es) |
AU (1) | AU2021230370A1 (es) |
BR (1) | BR112022017501A2 (es) |
CA (1) | CA3173805A1 (es) |
IL (1) | IL296151A (es) |
MX (1) | MX2022010902A (es) |
WO (1) | WO2021178734A1 (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140748A (en) * | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
US20090054468A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Use 938 |
US20090053176A1 (en) * | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | New Combination 937 |
US20240067651A1 (en) * | 2019-10-10 | 2024-02-29 | Biohaven Therapeutics Ltd. | Prodrugs of myeloperoxidase inhibitors |
-
2021
- 2021-03-05 CN CN202180018420.0A patent/CN115916164A/zh active Pending
- 2021-03-05 JP JP2022552413A patent/JP2023519662A/ja active Pending
- 2021-03-05 MX MX2022010902A patent/MX2022010902A/es unknown
- 2021-03-05 US US17/907,784 patent/US20230130225A1/en active Pending
- 2021-03-05 AU AU2021230370A patent/AU2021230370A1/en active Pending
- 2021-03-05 IL IL296151A patent/IL296151A/en unknown
- 2021-03-05 BR BR112022017501A patent/BR112022017501A2/pt not_active Application Discontinuation
- 2021-03-05 WO PCT/US2021/020979 patent/WO2021178734A1/en unknown
- 2021-03-05 CA CA3173805A patent/CA3173805A1/en active Pending
- 2021-03-05 EP EP21764758.5A patent/EP4114370A4/en active Pending
- 2021-03-05 KR KR1020227033471A patent/KR20220149709A/ko active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
IL296151A (en) | 2022-11-01 |
JP2023519662A (ja) | 2023-05-12 |
US20230130225A1 (en) | 2023-04-27 |
AU2021230370A1 (en) | 2022-10-20 |
EP4114370A4 (en) | 2024-03-20 |
CN115916164A (zh) | 2023-04-04 |
KR20220149709A (ko) | 2022-11-08 |
EP4114370A1 (en) | 2023-01-11 |
CA3173805A1 (en) | 2021-09-10 |
WO2021178734A1 (en) | 2021-09-10 |
BR112022017501A2 (pt) | 2022-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023007193A (es) | Inhibidores de enpp1 y su uso para el tratamiento del cancer. | |
MX2021009269A (es) | Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria. | |
ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
MX2023008453A (es) | Metodos de tratamiento para el abuso de sustancias. | |
MX2022015900A (es) | Inhibidores de alk2 para el tratamiento de la anemia. | |
MX2022010483A (es) | Metodos de tratamiento del complejo de esclerosis tuberosa con cannabidiol y everolimus. | |
JOP20220054A1 (ar) | علاج اعتلال الدماغ syngap1 | |
ZA202006072B (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
MX2022010258A (es) | Composiciones y métodos para tratar la lesión renal. | |
MX2022011231A (es) | Inhibidor de cxcr4 para el tratamiento del sindrome de dificultad respiratoria aguda e infecciones virales. | |
MX2022010902A (es) | Metodo para tratar la esclerosis lateral amiotrofica con un inhibidor de la mieloperoxidasa. | |
WO2019139956A3 (en) | Prevention and treatment of organ fibrosis | |
MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
MX2020007817A (es) | Prevención y tratamiento del trastorno del sueño. | |
CL2021003303A1 (es) | Tratamiento para sinucleinopatías. | |
MX2022011725A (es) | Metodos para tratar una lesion pulmonar con inhibidores de cgrp. | |
MX2022012632A (es) | Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington. | |
MX2021009488A (es) | Uso de vibegron para tratar la vejiga hiperactiva. | |
MX2022008532A (es) | Inhibidores de hidrocarburo de arilo (ahr) y usos de estos. | |
MX2023005027A (es) | Regimenes para el tratamiento de los trastornos de la perdida de cabello con inhibidores de jak deuterados. | |
WO2022159028A3 (en) | Method of treating a skin disorder by administering an amiloride derivative | |
MX2023006704A (es) | Composiciones dsg2 y metodos para el tratamiento de covid-19. | |
BR112022019858A2 (pt) | Métodos de tratamento de esclerose sistêmica | |
MX2022016174A (es) | Composiciones y metodos para tratar un trastorno obsesivo-compulsivo. | |
WO2023230451A3 (en) | Methods of treating spinocerebellar ataxias |